Angiotensin II type 1 and 2 receptors and lymphatic vessels modulate lung remodeling and fibrosis in systemic sclerosis and idiopathic pulmonary fibrosis

Imagem de Miniatura
Arquivos
art_PARRA_Angiotensin_II_type_1_and_2_receptors_and_2014.PDF (3.07 MB)
Citações na Scopus
15
Tipo de produção
article
Data de publicação
2014
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Autores
Citação
CLINICS, v.69, n.1, p.47-54, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVE: To validate the importance of the angiotensin II receptor isotypes and the lymphatic vessels in systemic sclerosis and idiopathic pulmonary fibrosis. METHODS: We examined angiotensin II type 1 and 2 receptors and lymphatic vessels in the pulmonary tissues obtained from open lung biopsies of 30 patients with systemic sclerosis and 28 patients with idiopathic pulmonary fibrosis. Their histologic patterns included cellular and fibrotic non-specific interstitial pneumonia for systemic sclerosis and usual interstitial pneumonia for idiopathic pulmonary fibrosis. We used immunohistochemistry and histomorphometry to evaluate the number of cells in the alveolar septae and the vessels stained by these markers. Survival curves were also used. RESULTS: We found a significantly increased percentage of septal and vessel cells immunostained for the angiotensin type 1 and 2 receptors in the systemic sclerosis and idiopathic pulmonary fibrosis patients compared with the controls. A similar percentage of angiotensin 2 receptor positive vessel cells was observed in fibrotic non-specific interstitial pneumonia and usual interstitial pneumonia. A significantly increased percentage of lymphatic vessels was present in the usual interstitial pneumonia group compared with the non-specific interstitial pneumonia and control groups. A Cox regression analysis showed a high risk of death for the patients with usual interstitial pneumonia and a high percentage of vessel cells immunostained for the angiotensin 2 receptor in the lymphatic vessels. CONCLUSION: We concluded that angiotensin II receptor expression in the lung parenchyma can potentially control organ remodeling and fibrosis, which suggests that strategies aimed at preventing high angiotensin 2 receptor expression may be used as potential therapeutic target in patients with pulmonary systemic sclerosis and idiopathic pulmonary fibrosis.
Palavras-chave
Systemic Sclerosis, Idiopathic Pulmonary Fibrosis, Immunohistochemistry, Angiotensin, Survival
URI
https://observatorio.fm.usp.br/handle/OPI/5456
Referências
  1. AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200
  2. AGUSTI C, 1992, THORAX, V47, P1035, DOI 10.1136/thx.47.12.1035
  3. American Thoracic Society, 2000, AM J RESP CRIT CARE, V161, P646
  4. [American Thoracic Society/European Respiratory Society American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS) and the European Respiratory Society (ERS) ERS Executive Committee], 2002, AM J RESP CRIT CARE, V1652, P277
  5. [Anonymous], 1980, ARTHRITIS RHEUM, V23, P581
  6. Carey RM, 2005, CURR OPIN NEPHROL HY, V14, P67, DOI 10.1097/00041552-200501000-00011
  7. Cottin V, 2003, EUR RESPIR J, V22, P245, DOI 10.1183/09031936.03.00026703
  8. D'Amore A, 2005, HYPERTENSION, V46, P1347, DOI 10.1161/.01.HYP.0000193504.51489.cf
  9. de Gasparo M, 2002, DRUGS, V62, P1, DOI 10.2165/00003495-200262991-00001
  10. de Souza RBC, 2009, RESPIRATION, V77, P389, DOI 10.1159/000156958
  11. Dohi M, 2000, AM J RESP CRIT CARE, V162, P2302
  12. Douglas WW, 2001, AM J RESP CRIT CARE, V164, P1182
  13. Ebina M, 2004, AM J RESP CRIT CARE, V169, P1203, DOI 10.1164/rccm.200308-1111OC
  14. Flaherty KR, 2003, AM J RESP CRIT CARE, V167, P1410, DOI 10.1164/rccm.200204-373OC
  15. Horiuchi M, 2006, ENDOCR J, V53, P1, DOI 10.1507/endocrj.53.1
  16. Hsia CCW, 2010, AM J RESP CRIT CARE, V181, P394, DOI 10.1164/rccm.200809-1522ST
  17. Ito I, 2005, AM J RESP CRIT CARE, V171, P632, DOI 10.1164/rccm.200403-417OC
  18. Kaschina E, 2003, BLOOD PRESSURE, V12, P70, DOI 10.1080/08037050310001057
  19. Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301
  20. Keogh KA, 2005, EUR RESPIR J, V25, P708, DOI 10.1183/09031936.05.00090204
  21. Kim DS, 2002, SARCOIDOSIS VASC DIF, V19, P121
  22. LEROY EC, 1988, J RHEUMATOL, V15, P202
  23. Li XP, 2007, CURR PHARM DESIGN, V13, P1257, DOI 10.2174/138161207780618867
  24. Mandal RV, 2008, HUM PATHOL, V39, P1234, DOI 10.1016/j.humpath.2008.01.002
  25. Marshall RP, 2004, AM J PHYSIOL-LUNG C, V286, pL156, DOI 10.1152/ajplung.00313.2002
  26. Meinecke AK, 2012, BLOOD, V119, P5931, DOI 10.1182/blood-2011-12-396895
  27. Miura S, 2005, J BIOL CHEM, V280, P18237, DOI 10.1074/jbc.M500639200
  28. Miura SI, 2000, EMBO J, V19, P4026, DOI 10.1093/emboj/19.15.4026
  29. Molteni A, 2007, CURR PHARM DESIGN, V13, P1307, DOI 10.2174/138161207780618777
  30. Nakashima Hidekatsu, 2006, Current Vascular Pharmacology, V4, P67, DOI 10.2174/157016106775203126
  31. Oro C, 2007, PHARMACOL THERAPEUT, V113, P210, DOI 10.1016/j.pharmthera.2006.10.001
  32. Papiris SA, 1997, RESPIRATION, V64, P81
  33. Park JH, 2007, AM J RESP CRIT CARE, V175, P705, DOI 10.1164/rccm.200607-912OC
  34. Parra ER, 2005, LUNG, V183, P363, DOI 10.1007/s00408-005-2548-1
  35. Parra ER, 2012, BRAZ J MED BIOL RES, V45, P466
  36. QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693
  37. Raghu G, 2011, AM J RESP CRIT CARE, V183, P788, DOI 10.1164/rccm.2009-040GL
  38. Reudelhuber TL, 2005, HYPERTENSION, V46, P1261, DOI 10.1161/01.HYP.0000193498.07087.83
  39. Rocco PRM, 2001, AM J RESP CRIT CARE, V164, P1067
  40. Ruiz-Ortega M, 2006, CURR OPIN NEPHROL HY, V15, P159, DOI 10.1097/01.mnh.0000203190.34643.d4
  41. Ruiz-Ortega M, 2006, NEPHROL DIAL TRANSPL, V21, P16, DOI 10.1093/ndt/gfi265
  42. Schuttert JB, 2003, PFLUG ARCH EUR J PHY, V446, P387, DOI 10.1007/s00424-003-1026-y
  43. Tansey D, 2004, HISTOPATHOLOGY, V44, P585, DOI 10.1111/j.1365-2559.2004.01896.x
  44. Uhal BD, 2007, CURR PHARM DESIGN, V13, P1247, DOI 10.2174/138161207780618885
  45. Wang RQ, 2000, AM J PHYSIOL-LUNG C, V279, pL143
  46. WELLS AU, 1994, AM J RESP CRIT CARE, V149, P1583
  47. Yamadori I, 2002, RHEUMATOL INT, V22, P89, DOI 10.1007/s00296-002-0204-0
  48. Yamashita M, 2009, HUM PATHOL, V40, P542, DOI 10.1016/j.humpath.2008.06.031
  49. Zhu YC, 2003, CLIN EXP PHARMACOL P, V30, P911, DOI 10.1111/j.1440-1681.2003.03942.x

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - ODS/03